Moreover, in HNSCC, IFIT3 regulates EMT and cancer stem cells by targeting PD-L1 through the PI3K/AKT pathway [68] and may participate in responses of HNSCC cells to EGFR/ERBB inhibition [81]. The gene discussed is IFIT3; the disease is cancer.